Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA Pharmaceuticals's Other Operating Expense for the
three
months ended in Jun. 2026 was MXN0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN0 Mil.
ACADIA Pharmaceuticals's quarterly Other Operating Expense
declined
from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN-0 Mil) but then
increased
from Mar. 2026 (MXN-0 Mil) to Jun. 2026 (MXN0 Mil).
ACADIA Pharmaceuticals's annual Other Operating Expense
declined
from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN-0 Mil) but then
stayed the same
from Dec. 2024 (MXN-0 Mil) to Dec. 2025 (MXN-0 Mil).
ACADIA Pharmaceuticals Other Operating Expense Related Terms
ACADIA Pharmaceuticals Other Operating Expense Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of MXN0 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Other Operating Expense of MXN0 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Other Operating Expense too high?
ACADIA Pharmaceuticals' current Other Operating Expense is MXN0 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Other Operating Expense compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Other Operating Expense of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Other Operating Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN396.51, compared to a current price of MXN453.75 — trading 14.4% above its estimated fair value. The current Other Operating Expense is MXN0 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Other Operating Expense is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN453.75 is trading 14.4% above its estimated GF Value™ of MXN396.51.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for MEX:ACAD:
Other Operating Expense: MXN0 Mil
GF Value™: MXN396.51 vs. price of MXN453.75 (14.4% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
71GF Score
Get the complete analysis for MEX:ACAD
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
